Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220306975ELECTROLYTE-CONTAINING ALCOHOLIC BEVERAGES
US 29.09.2022
Int.Class C12G 3/05
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
GWINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H106
3Preparation of other alcoholic beverages
04by mixing, e.g. for preparation of liqueurs
05with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
Appl.No 17707008 Applicant JHO INTELLECTUAL PROPERTY HOLDINGS, LLC Inventor John H Owoc

A hard seltzer is made by dissolving a sodium ion source in an aqueous ethanol solution, wherein the aqueous ethanol solution comprises from 1% to 14% by volume of ethanol; dissolving a potassium ion source in the aqueous ethanol solution; dissolving a magnesium ion source in the aqueous ethanol solution; and carbonating the aqueous ethanol solution to produce the hard seltzer. The sodium ion source, the potassium ion source, and the magnesium ion source are used in amounts effective to provide a hard seltzer comprising 20 to 400 mg/serving of sodium ions, 20 to 400 mg/serving of potassium ions; and 3 to 400 mg/serving of magnesium ions.

2.20220304895TABLET HAVING A TWO-DIMENSIONAL IDENTIFIER
US 29.09.2022
Int.Class A61J 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
3Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
Appl.No 17702435 Applicant Laxxon Medical AG Inventor Klaus KÜHNE

A solid dosage form for active ingredient release can be a preparation for medical, dental or cosmetic purposes, and is preferably a tablet. The solid dosage form comprises a three-dimensional base body which comprises an active ingredient. The solid dosage form further comprises a portion having a structure forming a two-dimensional identifier, such as, for instance, a QR code.

3.20220305026USE OF POLAPREZINC IN PREPARING DRUG FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER
US 29.09.2022
Int.Class A61K 31/555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
555containing heavy metals, e.g. hemin, hematin, melarsoprol
Appl.No 17829633 Applicant Jiangnan University Inventor Yongquan CHEN

The present disclosure discloses use of polaprezinc (Pola) in preparing a drug for treating castration-resistant prostate cancer (CRPC) and belongs to the technical field of biological medicine. The present disclosure provides a new strategy for preparing the drug for treating the CRPC by combining the Pola with an androgen receptor antagonist for the first time and conducts a multi-angle and multi-level verification research. A drug composition combining the polaprezinc and the androgen receptor antagonist can be used for treating castration-resistant prostate cancer, remarkably improves an effect of enzalutamide in inhibiting the castration-resistant prostate cancer, realizes new use of the old drug, can greatly shorten time from drug discovery to clinical transformation, and has important clinical treatment significance.

4.20220304918Oral Compositions Comprising Hops And Sweeteners
US 29.09.2022
Int.Class A61K 8/9789
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
96containing materials, or derivatives thereof, of undetermined constitution
97from algae, fungi, lichens or plants; from derivatives thereof
9783Angiosperms
9789Magnoliopsida
Appl.No 17704027 Applicant The Proctor & Gamble Company Inventor Arif Ali Baig

Oral care compositions including hops, first sweetener, and second sweetener. Oral care compositions including hops, a first sweetener with a first peak intensity time, and the first peak intensity time is earlier than a peak intensity time of sucrose and/or a second sweetener with a second peak intensity time, and the second peak intensity time is later than a peak intensity time of sucrose.

5.20220306646Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors
US 29.09.2022
Int.Class C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 17215468 Applicant Daljit Singh Dhanoa Inventor Daljit Singh Dhanoa

The present invention is concerned with novel deuterated Angiotensin-Converting Enzyme-2 (ACE-2) inhibitors of general structural formula I, their optically active enantiomers and diastereoisomers, and pharmaceutical salts and compositions thereof, as well as combination therapies which include compounds of the present invention,

embedded image

These compounds have high potency and selectivity for Angiotensin-Converting Enzyme-2 (ACE-2) inhibition, and are useful in the treatment of infectious respiratory diseases including the pandemic disease Covid-19, Severe Acute Respiratory Syndrome (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS-CoV), and other diseases caused by coronaviruses.

6.WO/2022/200468USE OF PANTETHINE FOR THE TREATMENT OF SARS COV-2 INFECTIONS
WO 29.09.2022
Int.Class A61K 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
Appl.No PCT/EP2022/057693 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor LAFORGE, Mireille
SARS-CoV and SARS-CoV-2 share similar pathogenic pathways that interact with pathways of cellular cholesterol metabolism. Depletion of cholesterol from cell membranes reduced the infectivity of SARS-CoV by 90%. Several studies reported that pantethine was able to reduce total cholesterol levels and total fatty acids synthesis but its anti-SARS CoV-2 activity has never been investigated. The inventors now demonstrate that pantethine is highly effective in the control of SARS-CoV-2 infections in vitro. In particular, the inventors show that the effect of pathethine on the inhibition of the replication of SARS-CoV-2 is interested at the dose of 100 μM (inhibition is around 76%) and the most effective concentration is 1000 μM (inhibition is around 98%). Pantethine treatments were able to reduce significantly the expression of the viral Spike and Nucleocapsid proteins and the accessory proteins ORF6. Thus the present invention relates to the use of pantethine for the treatment of a SARS CoV-2 infection.
7.WO/2022/200858TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE
WO 29.09.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/IB2022/000155 Applicant SPECIFIC BIOLOGICS INC. Inventor STEAD, Brent, E.
Provided herein are compositions and methods of using chimeric nucleases comprising an I-TevI nuclease domain and a Cas domain for the targeting of oncogenes.
8.WO/2022/200303METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS
WO 29.09.2022
Int.Class A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
Appl.No PCT/EP2022/057408 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor BENSUSSAN, Armand
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.
9.WO/2022/199028GADOLINIUM CHELATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO 29.09.2022
Int.Class C08F 8/42
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
8Chemical modification by after-treatment
42Introducing metal atoms or metal-containing groups
Appl.No PCT/CN2021/127915 Applicant SOUTH MEDICAL UNIVERSITY Inventor SHEN, Zheyu
A gadolinium chelate, a preparation method therefor, and an application thereof. The gadolinium chelate is a complex formed by chelation of gadolinium ions and macromolecules. The macromolecules comprise any one of or a copolymer or mixture of two or more of carboxylic acid-containing high-molecular polymers, amino-containing high-molecular polymers, hydroxyl-containing high-molecular polymers, polyester high-molecular polymers, polyether high-molecular polymers, polyamide high-molecular polymers, proteins, polypeptides, and polysaccharides. The gadolinium ions and the macromolecules form the gadolinium chelate by means of chelation. The gadolinium chelate is a water-soluble macromolecular drug, can improve a longitudinal relaxation rate r1 and reduce a ratio of r2/r1, has good water-solubility and high stability, and meanwhile, can exhibit a good imaging effect in a short period of time and shorten an MRI time.
10.WO/2022/200663USE OF ALBUMIN FOR THE TREATMENT OF DEFECTIVE B-CELL FUNCTION
WO 29.09.2022
Int.Class A61K 38/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
38Albumins
Appl.No PCT/ES2022/070171 Applicant GRIFOLS WORLDWIDE OPERATIONS LIMITED Inventor ARROYO PEREZ, Vicente
The present invention relates to a composition comprising human albumin for regulating B-cell function in a patient suffering from systemic inflammatory response syndrome, in which the albumin is administered to the patient in a dose sufficient to increase B-cell receptor density in a B-cell population.